Obestatin affords cardioprotection to the ischemic-reperfused isolated rat heart and inhibits apoptosis in cultures of similarly stressed cardiomyocytes

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 299, Issue 2, 2010, Pages

  Alloatti, Giuseppe ^a,b   Arnoletti, Elisa ^a   Bassino, Eleonora ^a   Penna, Claudia ^a   Perrelli, Maria Giulia ^a   Ghé, Corrado ^a   Muccioli, Giampiero ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Istituto Nazionale per la Ricerca Cardiovascolare (INRC)   (Italy)

Author keywords

Ischemia reperfusion; Myocardial infarction; Obestatin receptors

Indexed keywords

GHRELIN; HORMONE RECEPTOR; IODINE 125; OBESTATIN; OBESTATIN RECEPTOR; OBESTATIN[23-1]; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; GENE EXPRESSION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; TISSUE CULTURE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; APOPTOSIS; CASPASE 3; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; PEPTIDE HORMONES; PEPTIDES; PERFUSION; PROTEIN KINASE C-DELTA; PROTEIN KINASE C-EPSILON; PROTEIN KINASE INHIBITORS; RATS; RECEPTORS, GHRELIN; SIGNAL TRANSDUCTION; TIME FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 77955455608     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00800.2009     Document Type: Article

References (65)

1. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 270: 27489-27494, 1995.
2. Alloatti G, Penna C, Gallo MP, Levi RC, Bombardelli E, Appendino G. Differential effects of Paclitaxel and derivatives on guinea pig isolated heart and papillary muscle. J Pharmacol Exp Ther 284: 561-567, 1998.
3. Aragno M, Mastrocola R, Alloatti G, Vercellinatto I, Bardini P, Geuna S, Catalano MG, Danni O, Boccuzzi G. Oxidative stress triggers cardiac fibrosis in the heart of diabetic rats. Endocrinology 149: 380-388, 2008.
4. Baldanzi G, Filigheddu N, Cutrupi S, Catapano F, Bonissoni S, Fubini A, Malan D, Baj G, Granata R, Broglio F, Papotti M, Surico N, Bussolino F, Isgaard J, Deghenghi R, Sinigaglia F, Prat M, Muccioli G, Ghigo E, Graziani Ghrelin A. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/Akt. J Cell Biol 159: 1029-1037, 2002.
5. Bedendi I, Alloatti G, Marcantoni A, Malan D, Catapano F, Ghé C, Deghenghi R, Ghigo E, Muccioli G. Cardiac effects of ghrelin and its endogenous derivatives des-octanoyl ghrelin and des-Gln14-ghrelin. Eur J Pharmacol 476: 87-95, 2003.
6. Benso A, Broglio F, Marafetti Lucatello B L, Seardo MA, Granata R, Martina V, Papotti M, Muccioli G, Ghigo E. Ghrelin and synthetic growth hormone secretagogues are cardioactive molecules with identities and differences. Semin Vasc Med 4: 107-114, 2004.
7. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54: 146-151, 2005.
8. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 7: 248-254, 1976.
9. Budas GR, Churchill EN, Mochly-Rosen D. Cardioprotective mechanisms of PKC isozyme-selective activators and inhibitors in the treatment of ischemia-reperfusion injury. Pharmacol Res 55: 523-536, 2007.
10. Camina Campos JF JP, Caminos E, Dieguez C, Casanueva FF. Obestatin mediated proliferation of human retinal pigment epithelial cells: regulatory mechanisms. J Cell Physiol 211: 1-9, 2007.
11. Chang L, Ren Y, Liu X, Li WG, Yang Y, Geng B, Weintraub NL, Tang C. Protective effects of ghrelin on ischemia/reperfusion injury in isolated rat heart. J Cardiovasc Pharmacol 43: 165-170, 2004.
12. Chanoine JP, Wong AC, Barrios V. Obestatin, acylated and total ghrelin concentrations in the perinatal rat pancreas. Horm Res 66: 81-88, 2006.
13. Chartrel N, Alvear-Perez R, Leprince J, Iturrioz X, Reaux-Le Goazigo A, Audinot V, Chomarat P, Coge F, Nosjean O, Rodriguez M, Galizzi JP, Boutin JA, Vaudry H, Llorens-Cortes C. Comment on "Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake". Science 315: 766, 2007.
14. Eguchi M, Liu Y, Shin EJ, Sweeney G. Leptin protects H9c2 rat cardiomyocytes from H2O2-induced apoptosis. FEBS J 275: 3136-3144, 2008.
15. El Eter E, Al Tuwaijiri A, Hagar H, Arafa M. In vivo and in vitro antioxidant activity of ghrelin: attenuation of gastric ischemic injury in the rat. J Gastroenterol Hepatol 22: 1791-1799, 2007.
16. Frascarelli S, Ghelardoni S, Ronca-Testoni S, Zucchi R. Effect of ghrelin and synthetic growth hormone secretagogues in normal and ischemic rat heart. Basic Res Cardiol 98: 401-405, 2003.
17. Gallo MP, Levi R, Ramella R, Brero A, Boero O, Tota B, Alloatti G. Endothelium-derived nitric oxide mediates the antiadrenergic effect of human vasostatin-1 in rat ventricular myocardium. Am J Physiol Heart Circ Physiol 292: H2906-H2912, 2007.
18. Gelpi RJ, Morales C, Cohen MV, Downey JM. Xanthine oxidase contributes to preconditioning's preservation of left ventricular developed pressure in isolated rat heart: developed pressure may not be an appropriate end-point for studies of preconditioning. Basic Res Cardiol 97: 40-46, 2002.
19. Gourcerol H, Tache Y. Obestatin - a ghrelin associated peptide that does not hold its promise to suppress food intake and motility. Neurogastrenterol Motil 19: 161-165, 2007.
20. Granata R, Settanni F, Gallo D, Trovato L, Biancone L, Cantaluppi V, Nano R, Annunziata M, Campiglia P, Arnoletti E, Ghè C, Volante M, Papotti M, Muccioli G, Ghigo E. Obestatin promotes survival of pancreatic beta-cells and human islets and induces expression of genes involved in the regulation of β-cell mass and function. Diabetes 57: 967-979, 2008.
21. Gross ER, Gross GJ. Pharmacologic therapeutics for cardiac reperfusion injury. Expert Opin Emerg Drugs 12: 367-388, 2007.
22. Guo ZF, Ren AJ, Zheng X, Qin YW, Cheng F, Zhang J, Wu H, Yuan WJ, Zou I. Different responses of circulating ghrelin, obestatin levels to fasting, re-feeding and different food compositions, and their local expression in rats. Peptides 29: 1247-1254, 2008.
23. Hausenloy DJ, Mocanu MM, Yellon DM. Cross-talk between the survival kinases during early reperfusion: its contribution to ischemic preconditioning. Cardiovasc Res 63: 305-312, 2004.
24. Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol 288: H971-H976, 2005.
25. Herbert JM, Augereau JM, Gleye J, Maffrand JP. Chelerythrine is a potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun 172: 993-999, 1990.
26. Hollaar L, Van der Laarse A. Interference of the measurement of lactate dehydrogenase (LDH) activity in human serum and plasma by LDH from blood cells. Clin Chim Acta 99: 135-142, 1979.
27. Holst B, Egerod KL, Schild E, Vickers SP, Cheetham S, Gerlach LO, Storjohann L, Stidsen CE, Jones R, Beck-Sickinger AG, Schwartz TW. GPR39 signaling is stimulated by zinc ions but not by obestatin. Endocrinology 148: 13-20, 2007.
28. Huda MS, Durham BH, Wong SP, Deepak D, Kerrigan D, McCulloch P, Ranganath L, Pinkney J, Wilding JP. Plasma obestatin levels are lower in obese and post-gastrectomy subjects, but do not change in response to a meal. Int J Obes (Lond) 32: 129-135, 2008.
29. Iglesias MJ, Pineiro Blanco M, Gallego R, Dieguez C, Gualillo O, Gonzalez-Juanatey Lago F. Growth hormone releasing peptide (ghrelin) is synthesized and secreted by cardiomyocytes. Cardiovasc Res 62: 481-488, 2004.
30. Isgaard J, Johansson I. Ghrelin and GHS on cardiovascular applications/functions. J Endocrinol Invest 28: 838-842, 2005.
31. Kawczynska-Drozdz A, Olszanecki R, Jawien J, Brzozowski T, Pawlik WW, Korbut R, Guzik TJ. Ghrelin inhibits vascular superoxide production in spontaneously hypertensive rats. Am J Hypertens 19: 764-767, 2006.
32. Kumar S. The apoptotic cysteine protease CPP32. Int J Biochem Cell Biol 29: 393-396, 1997.
33. Kwak HJ, Park KM, Choi HE, Lim HJ, Park JH, Park HY. The cardioprotective effects of zileuton, a 5-lipoxygenase inhibitor, are mediated by COX-2 via activation of PKCδ. Cell Signal 22: 80-87, 2010.
34. Lauwers E, Landuyt B, Arckens L, Schoofs L, Luyten W. Obestatin does not activate orphan G protein-coupled receptor GPR39. Biochem Biophys Res Commun 351: 21-25, 2006.
35. Leite-Moreira AF, Rocha-Sousa A, Henriques-Coelho T. Cardiac, skeletal, and smooth muscle regulation by ghrelin. Vitam Horm 77: 207-238, 2008.
36. Li L, Zhang L, Pang YZ, Pan CS, Oi YF, Chen L, Wang X, Tang CS, Zhang J. Cardioprotective effects of ghrelin and des-octanoyl ghrelin on myocardial injury induced by isoproterenol in rats. Acta Pharmacol Sinica 27: 527-535, 2006.
37. Loor G, Schumacker PT. Role of the hypoxia-inducible factor in cell survival during myocardial ischemia-reperfusion. Cell Death Differ 15: 696-690, 2008.
38. Ma XL, Gao F, Liu GL, Lopez BL, Christopher TA, Fukuto JM, Wink DA, Feelisch M. Opposite effects of nitric oxide and nitroxyl on postischemic myocardial injury. Proc Natl Acad Sci USA 96: 14617-14622, 1999.
39. Marleau S, Mulumba M, Lamontahne D, Ong H. Cardiac and peripheral actions of growth hormone and its releasing peptides: relevance for the treatment of cardiomyopathies. Cardiovasc Res 69: 26-35, 2006.
40. Maser RE, Lenhard MJ. An overview of the effect of weight loss on cardiovascular autonomic function. Curr Diabetes Rev 3: 204-211, 2007.
41. McKee KK, Tan CP, Palyha OC, Liu J, Feighner SD, Hreniuk DL, Smith RG, Howard AD, Van der Ploeg LH. Cloning and characterization of two human G protein-coupled receptor genes (GPR38 and GPR39) related to the growth hormone secretagogue and neurotensin receptors. Genomics 46: 426-434, 1997.
42. Mizukami Y, Ono K, Du CK, Aki T, Hatano N, Okamoto Y, Ikeda Y, Ito H, Hamano K, Morimoto S. Identification and physiological activity of survival factor released from cardiomyocytes during ischemia and reperfusion. Cardiovasc Res 79: 89-99, 2008.
43. Mondal MS, Toshinai K, Ueno H, Koshinaka K, Nakazato M. Characterization of obestatin in rat and human stomach and plasma and its lack of acute effect on feeding behaviour in rodents. J Endocrinol 198: 339-346, 2008.
44. Muccioli G, Baragli A, Granata R, Papotti M, Ghigo E. Heterogeneity of ghrelin/growth hormone secretagogue receptors. Toward the understanding of the molecular identity of novel ghrelin/GHS receptors. Neuroendocrinology 86: 147-164, 2007.
45. Muccioli G, Pons N, Ghè C, Catapano F, Granata R, Ghigo E. Ghrelin and des-acyl ghrelin both inhibit isoproterenol-induced lipolysis in rat adipocytes via a non-type growth hormone secretagogue receptor. Eur J Pharmacol 498: 27-35, 2004.
46. Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev 88: 581-609, 2008.
47. Murphy E. Primary and secondary signaling pathways in early preconditioning that converge on the mitochondria to produce cardioprotection. Circ Res 94: 7-16, 2004.
48. Ozbay Y, Aydin S, Dagli AF, Akbulut M, Dagli N, Kilic N, Rahman A, Sahin I, Polat V, Ozercan HI, Arslan N, Sensoy D. Obestatin is present in saliva: alterations in obestatin and ghrelin levels of saliva and serum in ischemic heart disease. BMB Rep 41: 55-61, 2008.
49. Pan W, Tu H, Kastin AJ. Differential BBB interaction of three ingestive peptides: obestatin, ghrelin and adiponectin. Peptides 27: 911-916, 2006.
50. Paravicini TM, Touyz RM. NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care 31: S170-S180, 2008.
51. Pazos Y, Alvarez Camina JP Casanueva FF CJ. Stimulation of extracellular signal-regulated kinases and proliferation in the human gastric cancer cells KATO-III by obestatin. Growth Factors 25: 373-381, 2008.
52. Pemberton C, Richards AM. Biochemistry of ghrelin precursor peptides. Vitam Horm 77: 13-30, 2008.
53. Pemberton C, Wimalasena P, Yandle T, Soule S, Richards M. C-terminal pro-ghrelin peptides are present in the human circulation. Biochem Biophys Res Commun 310: 567-573, 2003.
54. Pettersson I, Muccioli G, Granata R, Deghenghi R, Ghigo E, Ohlsson C, Isgaard J. Natural (ghrelin) and synthetic (hexarelin) GH secretagogues stimulate H9c2 cardiomyocyte cell proliferation. J Endocrinol 175: 201-209, 2002.
55. Qi X, Li L, Yang G, Liu J, Li K, Tang Y, Liou H, Boden G. Circulating obestatin levels in normal subjects and in patients with impaired glucose regulation and type 2 diabetes mellitus. Clin Endocrinol 66: 593-597, 2007. (Pubitemid 46434942)
56. Rakhit RD, Edwards RJ, Mockridge JW, Baydoun AR, Wyatt AW, Mann GE, Marber MS. MCP-1 induces cardioprotection against ischaemia/reperfusion injury: role of reactive oxygen species. Am J Physiol Heart Circ Physiol 278: H1211-H1217, 2000.
57. Seoane LM, Al-Massadi O, Pazos Y, Pagotto U, Casanueva FF. Central obestatin administration does not modify either spontaneous or ghrelin-induced food intake in rats. J Endocrinol Invest 29: RC13-RC15, 2006.
58. Soares JB, Leite-Moreira AF. Ghrelin, des-acyl ghrelin and obestatin: three pieces of the same puzzle. Peptides 29: 1255-1270, 2008.
59. Tang SQ, Jiang QY, Zhang YL, Zhu XT, Shu G, Gao P, Feng DY, Wang XQ, Dong XY. Obestatin: its physicochemical characteristics and physiological functions. Peptides 29: 639-645, 2008.
60. Tong H, Chen W, Steenbergen C, Murphy E. Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C. Circ Res 87: 309-315, 2000.
61. Tremblay F, Perreault M, Klaman LD, Tobin JF, Smith E, Gimeno RE. Normal food intake and body weight in mice lacking the G protein-coupled receptor GPR39. Endocrinology 148: 501-506, 2007.
62. Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wymann MP, Williams RL. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 6: 909-919, 2000.
63. Wilson PW. Diabetes mellitus and coronary heart disease. Am J Kidney Dis 32: S89-100, 1998.
64. Zhang JV, Ren PG, Avsian-Kretchmer O, Luo CW, Rauch R, Klein C, Hsueh AJW. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 310: 996-999, 2005.
65. Zhao H, Liu G, Wang Q, Ding L, Cai H, Jiang H, Xin Z. Effect of ghrelin on human endothelial cells apoptosis induced by high glucose. Biochem Biophys Res Commun 362: 677-681, 2007.